Psychopharmacology Practice Questions

Q: A patient presents with recurrent, unexpected panic attacks and persistent concern about additional attacks for the past month. What is the best treatment option?

SSRI. ***SSRI*** - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered first-line for **panic disorder** due to their efficacy in reducing the frequency and severity of panic attacks and associated anticipatory anxiety. - They work by increasing serotonin levels in the brain, helping to regulate mood and anxiety over time, with full effects typically seen after several weeks of consistent use. *Benzodiazepines* - While effective for acute panic attacks due to their rapid onset of action, **benzodiazepines** are generally not the best long-term treatment for panic disorder. - Their use carries risks of **dependence**, **tolerance**, and **withdrawal symptoms**, and they do not address the underlying mechanisms of panic disorder. *Tricyclic antidepressants* - **Tricyclic antidepressants (TCAs)** can be effective for panic disorder, but they are typically considered second-line due to a less favorable side effect profile compared to SSRIs. - Side effects such as **anticholinergic effects**, **cardiac effects**, and sedation can limit their tolerability. *Beta-blockers* - **Beta-blockers** can help manage the **physical symptoms of anxiety** like palpitations and tremors, but they do not treat the core psychological aspects of panic disorder. - They are generally used for performance anxiety or situational anxiety, not as a primary treatment for recurrent, unexpected panic attacks.

Q: A 35-year-old woman with major depressive disorder is started on fluoxetine. After two weeks, she develops restlessness, tremors, and hyperreflexia. What is the most likely cause?

Serotonin syndrome. ***Serotonin syndrome*** - The patient's symptoms of **restlessness**, **tremors**, and **hyperreflexia** after starting **fluoxetine** (an SSRI) are characteristic of **serotonin syndrome**, caused by excessive serotonin activity. - This condition is often precipitated by the introduction of a new serotonergic agent or an increase in the dosage of an existing one. *Neuroleptic malignant syndrome* - Characterized by **severe muscle rigidity**, **fever**, altered mental status, and autonomic instability, often associated with antipsychotic medications. - It does not typically present with the same constellation of motor and reflex symptoms as seen here with an SSRI. *Acute dystonia* - Involves **sustained muscle contractions** causing twisting and repetitive movements or abnormal postures, often occurring shortly after starting or increasing an antipsychotic. - It does not typically include the widespread neurological symptoms like hyperreflexia and generalized tremors observed in this patient. *Hypokalemia* - Can cause **muscle weakness**, cramps, and fatigue, and in severe cases, cardiac arrhythmias. - It does not explain the patient's neurological symptoms like restlessness, tremors, and hyperreflexia after starting fluoxetine.

Q: A 50-year-old female with bipolar disorder presents with severe euphoric mania. What is the first-line treatment?

Lithium. ***Lithium*** - **Lithium** is considered **first-line** for the treatment of **acute mania** and for **long-term maintenance** in bipolar disorder, especially for classic euphoric mania. - Its efficacy in stabilizing mood, reducing the frequency and severity of episodes, and decreasing suicidality is well-established. *Carbamazepine* - While effective in treating acute mania, **carbamazepine** is generally considered a **second-line agent** or an alternative for rapid cycling or mixed features rather than first-line. - It carries risks of side effects such as **aplastic anemia** and **agranulocytosis**, requiring close monitoring. *Valproate* - **Valproate (valproic acid)** is a widely used and effective treatment for acute mania, especially in patients with **rapid cycling**, mixed states, or who are unable to tolerate lithium. - However, **lithium** is often preferred as a first-line agent particularly for classic euphoric mania due to its comprehensive efficacy profile and established safety for long-term use with appropriate monitoring. *Lamotrigine* - **Lamotrigine** is primarily used for the **maintenance treatment of bipolar depression** and is **not effective for acute manic episodes**. - Initiating lamotrigine requires a **slow titration** due to the risk of **Stevens-Johnson syndrome**, making it unsuitable for acute management of severe mania.

Q: In the treatment of schizophrenia, why might a switch from a typical antipsychotic to an atypical antipsychotic be considered?

Reduced risk of extrapyramidal symptoms. ***Reduced risk of extrapyramidal symptoms*** - Atypical antipsychotics (second-generation) have a **lower affinity for D2 dopamine receptors** and a higher affinity for **serotonin 5-HT2A receptors** compared to typical antipsychotics. - This receptor profile results in a **significantly reduced risk of extrapyramidal symptoms (EPS)** like dystonia, akathisia, and parkinsonism, which are common with typical antipsychotics. *Increased dopamine receptor antagonism* - Atypical antipsychotics actually have **less potent D2 dopamine receptor antagonism** compared to typical antipsychotics, which is why they cause fewer extrapyramidal symptoms. - While they still block dopamine receptors, their **serotonin 5-HT2A antagonism** is believed to mitigate the severe D2 blockade effects. *Longer half-life allowing less frequent dosing* - The half-life of an antipsychotic is a property of the specific drug, not a defining characteristic that differentiates atypical from typical antipsychotics as a class. - Both typical and atypical antipsychotics include drugs with varying half-lives, and **extended-release formulations** are available for both types, not exclusively for atypical ones. *Some atypical antipsychotics may improve cognitive function* - While some atypical antipsychotics may show **modest improvements or stabilization of cognitive function** in some patients, this is not the primary or most common reason for switching from typical antipsychotics. - The most compelling reason for the switch is often to **reduce the burden of debilitating side effects** like EPS, which directly impact a patient's quality of life and adherence.

Q: A 45-year-old male with bipolar disorder who is well-controlled on lithium develops hypothyroidism. What is the most appropriate management?

Add levothyroxine. ***Add levothyroxine*** - Hypothyroidism is a known side effect of lithium therapy, but it can be effectively managed by adding **levothyroxine** while continuing lithium [1]. This allows the patient to maintain the benefits of lithium for bipolar disorder control. - The goal is to treat the hypothyroidism, not necessarily to stop the effective psychiatric treatment, especially when the bipolar disorder is **well-controlled**. *Discontinue lithium* - Discontinuing lithium would likely lead to a **relapse of bipolar disorder**, as the patient is described as "well-controlled" on the medication. - While lithium is the cause of hypothyroidism in this scenario, simply stopping it is not the most appropriate first-line management when the hypothyroidism is treatable. *Switch to valproate* - Switching to valproate may destabilize the patient's bipolar disorder, especially since they are currently **well-controlled on lithium**. - Valproate also has its own side effect profile and may not be as effective for all patients with bipolar disorder. *Reduce lithium dose* - Reducing the lithium dose might alleviate the hypothyroidism slightly, but it could **compromise the therapeutic efficacy** of lithium for bipolar disorder. - If hypothyroidism develops, the primary approach is to treat the thyroid dysfunction directly rather than risk bipolar symptom recurrence [1].

Q: A female patient on lithium for bipolar disorder for 6 months presents with seizures, tremors, confusion, and weakness. What is the primary investigation to diagnose lithium toxicity?

serum lithium level. ***Serum lithium level*** - An elevated **serum lithium level** is the definitive diagnostic test for lithium toxicity, directly measuring the concentration of the drug in the patient's blood. - The symptoms of seizures, tremors, confusion, and weakness are all classic signs of **lithium neurotoxicity**, making the measurement of its blood concentration critical. - Therapeutic range: 0.6-1.2 mEq/L; toxicity typically occurs at levels >1.5 mEq/L. *Serum electrolytes* - While lithium toxicity can affect **electrolyte balance** (e.g., causing hyponatremia due to renal effects), measuring electrolytes alone is not sufficient to diagnose lithium toxicity. - Electrolytes should be checked as **dehydration and hyponatremia can precipitate toxicity**, but they don't directly measure lithium concentration. - Changes in electrolytes are often secondary and not directly indicative of the circulating **lithium concentration**. *ECG* - An **ECG** can reveal cardiac effects of lithium toxicity, such as **T-wave inversions** or **QT prolongation**, but it does not directly measure lithium levels or confirm the diagnosis. - Cardiac abnormalities are usually seen in severe toxicity and are not the primary diagnostic marker. - ECG is important for monitoring cardiac complications but is not diagnostic of lithium toxicity itself. *MRI* - An **MRI of the brain** might be considered in cases of severe neurological symptoms like seizures or altered mental status to rule out other causes or assess for **cerebral edema**, but it does not diagnose lithium toxicity itself. - It is a supportive or exclusionary test, not the primary diagnostic tool for lithium overdose.

Q: What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Fluphenazine. ***Fluphenazine*** - **Fluphenazine** is available as a **long-acting injectable** (LAI) formulation, specifically **fluphenazine decanoate**, making it an ideal choice for patients with **poor oral absorption** or adherence issues. - Its **depot injection** bypasses the need for oral intake, ensuring therapeutic drug levels are maintained over several weeks. *Clozapine* - **Clozapine** is an **oral antipsychotic** and requires consistent oral intake for efficacy. - It is often reserved for **treatment-resistant schizophrenia** and is not available in a long-acting injectable form suitable for poor oral absorption. *Sulpride* - **Sulpride** is primarily an **oral antipsychotic** and its administration relies on adequate oral absorption. - It is not available in a formulation that would circumvent issues of poor oral absorption. *Penfluridol* - **Penfluridol** is an **oral long-acting antipsychotic**, but it still requires oral administration. - While long-acting, its efficacy depends on the patient's ability to absorb the drug orally, which is compromised in this scenario.

Question 1

A patient presents with recurrent, unexpected panic attacks and persistent concern about additional attacks for the past month. What is the best treatment option?

Accepted Answer

SSRI

Answer

Benzodiazepines

Answer

Tricyclic antidepressants

Answer

Beta-blockers

Question 2

A 24-year-old male with obsessive-compulsive disorder, refractory to high-dose SSRIs, reports persistent intrusive thoughts and rituals. What are the next-line treatment options to evaluate?

Accepted Answer

Add atypical antipsychotic, continue SSRI

Answer

Add clomipramine, monitor ECG

Answer

Switch to SNRI, add CBT

Answer

Consider deep brain stimulation

Question 3

A 45-year-old man presents with auditory hallucinations and paranoid delusions. He has been on risperidone for 6 months with a partial response. What is the next best step in management?

Accepted Answer

Increase the dose of risperidone

Answer

Add a mood stabilizer

Answer

Start cognitive-behavioral therapy

Answer

Switch to clozapine

Question 4

A 35-year-old woman with major depressive disorder is started on fluoxetine. After two weeks, she develops restlessness, tremors, and hyperreflexia. What is the most likely cause?

Accepted Answer

Serotonin syndrome

Answer

Neuroleptic malignant syndrome

Answer

Acute dystonia

Answer

Hypokalemia

Question 5

A 50-year-old female with bipolar disorder presents with severe euphoric mania. What is the first-line treatment?

Accepted Answer

Lithium

Answer

Carbamazepine

Answer

Valproate

Answer

Lamotrigine

Question 6

In the treatment of schizophrenia, why might a switch from a typical antipsychotic to an atypical antipsychotic be considered?

Accepted Answer

Reduced risk of extrapyramidal symptoms

Answer

Increased dopamine receptor antagonism

Answer

Longer half-life allowing less frequent dosing

Answer

Some atypical antipsychotics may improve cognitive function

Question 7

A 50-year-old female presents with persistent depressive disorder and has not responded to SSRIs. What is the next best treatment option?

Accepted Answer

Switch to a tricyclic antidepressant as the next treatment option

Answer

Add an antipsychotic medication to the treatment

Answer

Start electroconvulsive therapy for treatment

Answer

Switch to a monoamine oxidase inhibitor for treatment

Question 8

A 45-year-old male with bipolar disorder who is well-controlled on lithium develops hypothyroidism. What is the most appropriate management?

Accepted Answer

Add levothyroxine

Answer

Discontinue lithium

Answer

Switch to valproate

Answer

Reduce lithium dose

Question 9

A female patient on lithium for bipolar disorder for 6 months presents with seizures, tremors, confusion, and weakness. What is the primary investigation to diagnose lithium toxicity?

Accepted Answer

serum lithium level

Answer

serum electrolytes

Answer

ECG

Answer

MRI

Question 10

What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Accepted Answer

Fluphenazine

Answer

Clozapine

Answer

Sulpride

Answer

Penfluridol

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?